Ridinilazole是一种新型的抗菌剂，作用于C. difficile，MIC范围为0.06-0.25 μg/mL(MIC90=8 μg/mL)。
CAS：308362-25-6
分子式：C24H16N6
分子量：388.42
纯度：98%
存储：Store at -20°C

Background:

Ridinilazole is a novel antibacterial with MICs range of 0.06-0.25 µg/mL (MIC90=8 µg/mL) against C. difficile.

Ridinilazole is a novel antibacterial that does not appear to act through the classical pathways associated with antibiotics, such as inhibition of cell wall, protein, lipid, RNA or DNA synthesis. Ridinilazole may impair cell division. Ridinilazole is bactericidal against C. difficile and exhibits a prolonged post-antibiotic effect. In susceptibility testing of 82 clinical isolates of C. difficile (including ribotype 027), Ridinilazole displays potent growth inhibition and has lower MICs [MIC range, 0.06-0.25 µg/mL; MIC for 90% of the organisms (MIC90), 0.125 µg/mL] than Metronidazole (MIC range, 0.125-8 µg/mL; MIC90, 8 µg/mL) or Vancomycin (MIC range, 0.5-4 µg/mL; MIC90, 2 µg/mL). Similarly, Ridinilazole is found to be more potent than Metronidazole or Vancomycin at inhibiting the growth of 50 ribotype-defined C. difficile strains. The activity of Ridinilazole against specific C. difficile ribotypes (including ribotypes 001, 002, 005, 014, 027, 054 and 106) is similar, with an MIC range of 0.06-0.5 µg/mL and an MIC90 of 0.125 µg/mL. In addition, Ridinilazole is more active against 11 ribotype 027 strains than either Metronidazole or Vancomycin[1].

In a hamster model of CDI with a once-daily dosing regimen, Ridinilazole displays greater efficacy than Vancomycin both against non-epidemic and epidemic strains of C. difficile. Similar to the twice-daily dosing study, plasma levels of Ridinilazole are below the level of detection, whereas caecal Ridinilazole concentrations are well above the MIC, thus demonstrating the non-absorbable nature of Ridinilazole and minimal systemic exposure[1].

[1]. Vickers RJ, et al. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 Aug;48(2):137-43.